ResMed
RMD
$238.19
-0.56%
ResMed Inc. designs and manufactures continuous positive airway pressure (CPAP) devices, masks, and accessories used to treat obstructive sleep apnea, and also sells residential care software for home medical equipment providers, operating within the Healthcare sector's Medical Instruments & Supplies industry. The company is the clear market leader in sleep apnea therapy, with a durable competitive moat built on a razor-and-blade model in which devices (~half of revenue) seed a high-margin, recurring mask and accessories franchise (~40%) that drives customer stickiness and replacement-cycle revenue. The current investor narrative centers on the durability of that mask franchise against competitive pressure from Philips' re-entry into the U.S. sleep device market, alongside a strategic portfolio reshaping highlighted by the $340 million acquisition of Noctrix Health, which adds a first-in-class non-invasive therapy for Restless Legs Syndrome. Sentiment is also being shaped by the company's aggressive capital returns — roughly $936 million of buybacks in the most recent quarter — and a recent post-earnings selloff that has left the stock consolidating well below its 52-week high despite solid mid-single-digit revenue growth.…
RMD
ResMed
$238.19
Related headlines
Investment Opinion: Should I buy RMD Today?
Rating: Hold with a constructive bias. ResMed is a high-quality, cash-generative market leader trading near the bottom of its multi-year valuation band (18.67x trailing PE versus 35.0x in mid-2023), but with revenue growth decelerated to 5.93% YoY and ten of seventeen analysts on Hold, the evidence supports patience rather than aggressive accumulation at $239.53. The core thesis is that the market has already de-rated the stock for a growth slowdown that is now fully reflected in the multiple, while the mask franchise's pricing power and $2.849 billion of TTM free cash flow provide a hard floor under the equity. Supporting evidence is concrete: the $264.33 average analyst target implies +10.4% upside with a $320 high target (+33.6%); net margin expanded to 29.57% from 26.10% a year earlier on a 61.53% gross margin; the balance sheet carries just 0.125 debt-to-equity with a 3.10 current ratio and $1.011 billion of cash; and the company repurchased $936.4 million of stock in a single quarter while paying a 1.24% dividend at a 22.95% payout ratio. Against that, the PEG of 2.00 shows investors still pay roughly 2x growth for a ~6% grower, and the 12.80x EV/EBITDA and 4.99x PS are only cheap relative to RMD's own history, not versus a reaccelerating peer set. The biggest risks that could invalidate the thesis are a Philips-driven loss of U.S. mask share that erodes the 61.53% gross margin, a growth stall toward low single digits that keeps the multiple pinned near 18x, and a headline-driven earnings gap like the roughly 9% single-session drop from $252.83 to $229.94 on October 30. This Hold would upgrade to Buy on a confirmed break above the $253-254 resistance with mask share stable, or if the forward PE compressed below 16x while free cash flow held above $2.5 billion; it would downgrade to Sell if revenue growth fell below 3% or gross margin slipped under 59%. On balance the stock is fairly valued to modestly undervalued relative to its own history but not versus its growth rate — a reasonable hold for existing owners, and a scale-in candidate only for patient investors comfortable with mid-single-digit compounding.
Sign up to view all
RMD 12-Month Price Forecast
ResMed presents a classic de-rating-versus-fundamentals tension: the stock has fallen from 35x to 18.67x trailing earnings as growth normalized to roughly 6%, yet margins are expanding, free cash flow is $2.849 billion, and the balance sheet carries almost no leverage. The $264.33 average target implies +10.4% upside, but with ten of seventeen analysts on Hold and a 2.3 recommendation mean, the Street is signaling fair value rather than opportunity. The single variable that matters most is mask share against Philips' U.S. re-entry — if the 61.53% gross margin holds, the current multiple looks like an overshoot; if it erodes, the 89% sleep revenue concentration leaves no offset. I would upgrade to bullish on a confirmed break above $253-254 with stable mask share and gross margin above 61.5%, and downgrade to bearish if revenue growth falls below 3% or gross margin breaks under 59%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ResMed's 12-month outlook, with a consensus price target around $264.33 and implied upside of +11.0% versus the current price.
Average Target
$264.33
20 analysts
Implied Upside
+11.0%
vs. current price
Analyst Count
20
covering this stock
Price Range
$210 - $320
Analyst target range
Seventeen analysts cover RMD, with a distribution of 9 Buy, 10 Hold, and 1 Sell, yielding a consensus recommendation of "buy" but a recommendation mean of 2.3 that leans decidedly neutral in practice. The average target price is $264.33, implying roughly +10.4% upside from the current $239.53, while consensus EPS estimates of $15.48 (range $14.92-$16.10) and revenue estimates of $7.06 billion frame a stable but unspectacular growth outlook. The heavy Hold weighting (10 of 17) signals that most analysts see the stock as fairly valued after its recovery from the spring lows, with the bullish minority betting on margin expansion and buyback-driven EPS growth rather than a reacceleration in the top line. The target range is wide — $210 low to $320 high, a spread of $110 or roughly 46% of the current price — indicating meaningful disagreement about the company's trajectory. The $320 high target likely assumes multiple re-expansion toward historical med-tech norms, sustained mask-share gains, successful integration of the Noctrix acquisition, and continued aggressive capital returns; the $210 low target prices in competitive share loss to Philips, margin compression, and a growth stall that keeps the multiple depressed. Recent institutional actions skew cautious: Canaccord Genuity downgraded to Hold from Buy on November 2, 2026, while RBC Capital upgraded to Outperform from Sector Perform in mid-September and KeyBanc has maintained Overweight — a mixed but net-neutral tape. The wide spread and Hold-heavy consensus imply moderate conviction and elevated uncertainty, meaning position sizing should account for the possibility that the stock remains range-bound between the $210 low target and the $253 technical resistance until a clearer growth catalyst emerges.
Bulls vs Bears: RMD Investment Factors
The bear case currently has slightly stronger near-term evidence: growth has decelerated to 5.93% YoY with a sequential decline, ten of seventeen analysts sit on Hold, and the stock has lagged SPY by 17.26% over twelve months. The bull case, however, is built on harder financial facts — expanding net margins (29.57% vs. 26.10%), $2.849 billion of TTM free cash flow, a 0.125 debt-to-equity balance sheet, and a PE of 18.67x near the bottom of a multi-year range that once reached 35x. The single most important tension is whether the mask/accessories franchise can hold share and pricing against Philips' U.S. re-entry; if it can, the current multiple looks like a de-rating overshoot, but if mask share erodes, the 89% revenue concentration in sleep means there is no second engine to offset it. The Noctrix acquisition ($340 million for a Restless Legs Syndrome therapy) is a credible attempt to diversify, but at $155 million of Residential Care Software revenue it is far too small to move the needle within twelve months.
Bullish
- Margins expanding despite slow growth: Net margin rose to 29.57% in the latest quarter from 26.10% a year earlier, and operating margin reached 32.02% with EBITDA margin at 41.40%. Gross margin held at 61.53% (up from 61.46%), showing the razor-and-blade mask franchise retains pricing power even as headline revenue growth moderates to 5.93% YoY.
- Valuation near multi-year lows: The trailing PE of 18.67x and forward PE of 18.11x sit far below the 35.0x of mid-2023, 28.8x in late 2024 and 24.9x in mid-2025, while price-to-free-cash-flow is ~15.6x versus 74-116x historically. At 12.80x EV/EBITDA and 4.99x PS, the market is pricing in very little optimism, leaving room for multiple repair if growth merely stabilizes.
- Fortress balance sheet and cash generation: Debt-to-equity is just 0.125, the current ratio is 3.10, and cash stood at $1.011 billion at quarter-end. Free cash flow is $2.849 billion TTM ($373.7 million in the latest quarter against only $48.7 million of capex), funding a 1.24% dividend (22.95% payout) and $936.4 million of quarterly buybacks entirely from internal cash.
- Analyst target implies double-digit upside: The $264.33 average target implies roughly +10.4% upside from $239.53, with a high target of $320 (+33.6%) reflecting a re-rating scenario. Nine of 17 analysts rate Buy and the consensus recommendation is "buy," with recent positive actions including RBC's upgrade to Outperform and KeyBanc's maintained Overweight.
Bearish
- Growth stuck in mid-single digits: Revenue grew only 5.93% YoY to $1.4148 billion and actually dipped 3.3% sequentially from Q4 2026's $1.4636 billion high-water mark. Consensus revenue of $7.06 billion and EPS of $15.48 frame a stable but unspectacular outlook, and the PEG ratio of 2.00 shows investors still pay 2x growth for a business expanding at roughly 6%.
- Philips re-entry threatens mask share: The core sleep franchise is roughly 89% of revenue ($1.260 billion of $1.415 billion), leaving the company highly exposed to a single market. Philips' re-entry into the U.S. sleep device market is the central competitive threat, and Zacks' Rank #3 (Hold) explicitly cites competitive pressures as a reason to stay on the sidelines.
- Hold-heavy, low-conviction consensus: Ten of 17 analysts rate Hold, producing a recommendation mean of 2.3 that leans neutral despite the "buy" label. Canaccord Genuity downgraded to Hold from Buy on November 2, 2026, and the $210-$320 target range spans $110, or roughly 46% of the current price, signaling genuine disagreement about the trajectory.
- Earnings headline sensitivity: The stock gapped roughly 9% in a single session from $252.83 on October 29 to $229.94 on October 30 around earnings, and remains 13.7% below its 52-week high of $277.67. With a 1-year relative strength of -17.26% versus SPY's +12.27%, the twelve-month trend is still one of underperformance and de-rating.
RMD Technical Analysis
RMD is in a recovery uptrend within a longer-term consolidation, having risen 18.65% over the past six months and 6.71% over three months, yet still down 4.99% over the trailing year. At $239.53, the stock trades at roughly 61% of its 52-week range (low $180.27 to high $277.67), positioning it in the upper-middle of the band — constructive but not extended, with meaningful overhead supply remaining before the prior high is challenged. The 1-year relative strength of -17.26% versus SPY (+12.27%) confirms the stock has lagged the market over twelve months, making the current setup a repair phase rather than a fresh breakout. Short-term momentum is clearly positive and accelerating: the stock is up 1.80% over one month versus a -2.26% decline for SPY, a +4.06% relative-strength spread, and up 6.71% over three months against SPY's -2.83% (a +9.54% spread). This positive 1-month and 3-month divergence against a negative 1-year trend is a classic mean-reversion/recovery signature rather than a trend reversal, suggesting the worst of the de-rating is behind it. The 6-month relative strength of +16.52% reinforces that buyers have been in control since the spring lows near $180, though the sharp single-day drop from $252.83 on October 29 to $229.94 on October 30 (a roughly 9% gap) shows the stock remains headline-sensitive around earnings. Key support sits at the 52-week low of $180.27, with secondary support near the $220-225 shelf that has repeatedly held since September; resistance is the $253-254 area (the late-October high) and then the 52-week high of $277.67. A breakout above $253 would confirm the recovery and open a path toward the prior high, while a breakdown below $220 would invalidate the uptrend and refocus attention on the $180 floor. With a beta of just 0.763, RMD is roughly 24% less volatile than the market, which supports larger position sizing for risk-budgeted portfolios but also means it will likely lag in strong risk-on rallies — consistent with its -17.26% 1-year relative underperformance.
Beta
0.76
0.76x market volatility
Max Drawdown
-33.8%
Largest decline past year
52-Week Range
$180-$278
Price range past year
Annual Return
-2.6%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -0.3% | -3.0% |
| 3m | +8.3% | -3.6% |
| 6m | +13.5% | -0.2% |
| 1y | -2.6% | +10.1% |
| ytd | -2.7% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
Revenue is growing steadily but at a moderating mid-single-digit pace: the most recent quarter (September 30, 2026) delivered $1.4148 billion, up 5.93% year-over-year from $1.3356 billion, and the trailing four quarters total roughly $5.73 billion ($1.423B + $1.431B + $1.464B + $1.415B). The sequential trend is essentially flat-to-slightly-down — Q4 2026's $1.4636 billion was the high-water mark, with the latest quarter dipping 3.3% sequentially — indicating growth is being driven by the recurring mask/accessories and software mix rather than accelerating device volumes. Segment data shows Sleep and Respiratory at $1.260 billion versus Residential Care Software at $155 million, meaning the core sleep franchise is roughly 89% of revenue and remains the sole meaningful growth engine. The 5.93% YoY growth is respectable for a scaled med-tech leader but well below the double-digit growth the market once awarded premium multiples, which explains the persistent valuation compression. Profitability remains excellent and is actually expanding: net income of $418.4 million in the latest quarter produced a 29.57% net margin, up from 26.10% a year earlier, while gross margin improved to 61.53% from 61.46% and operating margin reached 32.02%. The multi-quarter gross margin trajectory is stable-to-rising (58.84% in Q4 2026, 62.25% in Q3 2026, 61.53% latest), and EBITDA margin of 41.40% underscores the operating leverage inherent in the razor-and-blade model. For a medical device manufacturer, a ~61.5% gross margin and ~30% net margin are top-tier, reflecting pricing power in masks and a favorable mix shift toward higher-margin software and consumables. The balance sheet is fortress-like: debt-to-equity is just 0.125, the current ratio is 3.10, and cash stood at $1.011 billion at quarter-end. Free cash flow is robust at $2.849 billion TTM, with $373.7 million generated in the latest quarter against $48.7 million of capex, and ROE of 23.13% and ROA of 14.76% confirm high capital efficiency. The company funds growth, a 1.24% dividend yield (payout ratio 22.95%), and heavy buybacks ($936.4 million repurchased in Q1) entirely from internal cash generation, with interest coverage historically above 90x — financial risk is minimal.
Quarterly Revenue
$1.4B
2026-09
Revenue YoY Growth
+5.9%
YoY Comparison
Gross Margin
61.5%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Because ResMed is solidly profitable (net income of $418.4 million in the latest quarter and positive TTM earnings), I lead with the price-to-earnings ratio as the primary metric. The stock trades at 18.67x trailing earnings and 18.11x forward earnings — a narrow gap that implies the market is pricing in only modest earnings growth (roughly 3% implied EPS expansion), consistent with the mid-single-digit revenue trajectory and a mature, cash-generative business rather than a high-growth compounder. The PEG ratio of 2.00 suggests that even at a seemingly modest absolute multiple, investors are paying about 2x the growth rate, flagging that the cheap-looking PE is partly a function of slow growth rather than deep undervaluation. Against its own industry, RMD's 18.67x trailing PE and 4.99x PS sit at a discount to the premium multiples historically commanded by high-quality med-tech franchises, and its 12.80x EV/EBITDA and 5.81x EV/Sales are reasonable for a 61% gross-margin, 30% net-margin leader. The 4.28x price-to-book is elevated relative to the 0.125 debt-to-equity, reflecting an asset-light, high-ROE business model rather than leverage-driven risk. Historically, RMD's PE has compressed dramatically: it traded at 35.0x in mid-2023, 28.8x in late 2024, 24.9x in mid-2025, and now 18.67x — near the bottom of its multi-year band. Similarly, PS has fallen from 33.5x in mid-2022 to 4.99x today, and price-to-free-cash-flow sits at roughly 15.6x versus 74-116x in prior periods. This places the stock near historical valuation lows, which could signal either a genuine value opportunity (if growth stabilizes) or persistent de-rating tied to competitive and growth concerns — the market is clearly no longer pricing in optimistic expectations.
PE
18.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~50x
vs. Industry Avg
40.3x
Industry PE ~40.3x*
EV/EBITDA
12.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are modest but not zero. Revenue concentration is the standout: the Sleep and Respiratory segment generated $1.260 billion of the $1.415 billion latest quarter, roughly 89%, so a share loss in masks or devices has no offsetting buffer. Growth has decelerated to 5.93% YoY with a 3.3% sequential decline from the Q4 2026 peak of $1.4636 billion, and the PEG of 2.00 means the 18.67x PE is only "cheap" because growth is slow — if EPS expansion stalls near the ~3% implied by the 18.67x trailing versus 18.11x forward gap, the multiple has no fundamental support. Balance-sheet risk is minimal (debt-to-equity 0.125, current ratio 3.10, interest coverage historically above 90x), but the $936.4 million quarterly buyback pace consumes cash that could otherwise buffer a competitive shock, and the $340 million Noctrix deal introduces integration and reimbursement risk for an unproven RLS therapy. Market and competitive risks center on Philips' re-entry into the U.S. sleep device market, which could pressure both device volumes and the high-margin mask attach rate that underpins the 61.53% gross margin. Valuation compression is a live threat rather than a hypothetical: the PE has fallen from 35.0x in mid-2023 to 18.67x today, and PS from 33.5x in mid-2022 to 4.99x, showing the market has repeatedly marked the stock down as growth normalized. With a beta of 0.763 the stock is 24% less volatile than the market, but that cuts both ways — it has lagged SPY by 17.26% over twelve months and will likely continue to lag in risk-on rotations, while the 8.52 short ratio means negative headlines can produce outsized single-day moves, as the roughly 9% gap from $252.83 to $229.94 on October 30 demonstrated. The worst-case scenario is a Philips-driven mask share loss combined with a growth stall that keeps the multiple depressed: revenue growth slipping toward low single digits would compress the PE toward the analyst low-target implied level, and the stock would retest the $210 low target and potentially the 52-week low of $180.27. From the current $239.53, that represents roughly -12.3% to the $210 low target and -24.7% to the $180.27 floor, while a full re-rating to the historical max drawdown of -33.75% would imply a price near $158.70. The realistic downside in an adverse scenario is therefore -12% to -25%, with the $220-225 shelf as the first line of defense and $180 as the hard floor established at the spring lows.
FAQ
Ranked by severity, the first risk is competitive: Philips' re-entry into the U.S. sleep device market threatens the mask attach rate that supports the 61.53% gross margin, and with the Sleep and Respiratory segment at roughly 89% of the $1.415 billion latest quarter, there is no second engine to offset share loss. Second is growth and valuation risk — revenue decelerated to 5.93% YoY with a 3.3% sequential decline from the $1.4636 billion Q4 2026 peak, and the PE has already compressed from 35.0x to 18.67x, so a stall toward low single digits could pin the multiple near or below current levels. Third is headline and positioning risk: the stock gapped roughly 9% in one session from $252.83 to $229.94 on October 30, and an 8.52 short ratio can amplify selling on any guidance miss. Fourth is financial/strategic risk, though the smallest — debt-to-equity of 0.125 and interest coverage above 90x make balance-sheet stress remote, but the $340 million Noctrix acquisition carries integration and reimbursement uncertainty and the ~$936 million quarterly buyback consumes cash that could otherwise buffer a competitive shock.
The base case carries 55% probability with a $245-$275 target range, assuming revenue grows mid-single digits toward the $7.06 billion consensus, EPS lands near $15.48, and the forward PE holds in the 18-19x band — bracketing the $264.33 average target and the $277.67 52-week high. The bull case at 25% probability targets $285-$320, requiring mask share to hold against Philips, gross margin above 61.5%, and multiple expansion toward 20-21x forward EPS, consistent with the $320 high analyst target. The bear case at 20% probability targets $180-$210, driven by Philips-driven share loss, gross margin breaking below 59%, and growth slipping toward low single digits, aligning with the $210 low target and the $180.27 52-week low. The base case is most likely because it requires only that current trends persist — stable margins, continued buybacks, and no competitive shock — rather than any reacceleration; the key assumption is that the 61.53% gross margin holds.
The primary metric is the PE: 18.67x trailing and 18.11x forward, a narrow gap implying the market expects only about 3% EPS growth. That is dramatically below RMD's own history — 35.0x in mid-2023, 28.8x in late 2024, and 24.9x in mid-2025 — and price-to-free-cash-flow of roughly 15.6x compares with 74-116x in prior periods, placing the stock near multi-year valuation lows. Supporting multiples are similarly restrained at 12.80x EV/EBITDA, 4.99x PS, and 5.81x EV/Sales for a business with 61.53% gross and 29.57% net margins. The counterweight is the PEG of 2.00, which shows the seemingly cheap absolute multiple is largely a function of slow growth rather than deep undervaluation, and the 4.28x price-to-book is high only because the asset-light model carries almost no leverage. Net: the stock is fairly valued to modestly undervalued relative to its own history but not versus its growth rate — the market is pricing in a mature, mid-single-digit compounder with no reacceleration.
From a risk/reward standpoint RMD offers roughly +10.4% upside to the $264.33 average analyst target and up to +33.6% to the $320 high target, against downside of about -12.3% to the $210 low target and -24.7% to the $180.27 52-week low — a moderately asymmetric setup skewed by the low 0.763 beta. The quality underpinning is real: 29.57% net margin, $2.849 billion TTM free cash flow, and a 0.125 debt-to-equity balance sheet mean the equity has a hard cash-flow floor. The catch is that at 18.67x trailing and 18.11x forward earnings with a PEG of 2.00, you are paying about 2x growth for a ~6% grower, and ten of seventeen analysts sit on Hold with a 2.3 recommendation mean. It is a good buy primarily for patient, quality-oriented investors who can tolerate range-bound action between roughly $220 and $253 and who want defensive healthcare exposure — and a better buy on a confirmed break above $253-254 or a pullback toward the $220-225 support shelf.
RMD fits long-term holding far better than short-term trading. The business is in a mature growth stage — 5.93% YoY revenue growth with a 3.3% sequential dip from the Q4 2026 peak — meaning returns depend on margin expansion, buyback-driven EPS growth, and eventual multiple repair rather than rapid top-line compounding, all of which take quarters to play out. Volatility is low (beta 0.763, roughly 24% less than the market), which limits short-term trading opportunity but supports larger position sizing for risk-budgeted portfolios, and the 1.24% dividend at a 22.95% payout ratio is a modest income supplement rather than a reason to own it. Earnings visibility is decent given the recurring mask and accessories franchise, but the ~9% single-session gap on October 30 shows headline sensitivity around reports. A minimum holding period of 18-24 months is appropriate — long enough to capture a full cycle of buyback-driven EPS growth and any re-rating toward the $264-$320 target zone, while allowing time for the Philips competitive question to resolve.

